Sticky nanoparticles to fight heart disease developed

Image
Press Trust of India Washington
Last Updated : Feb 19 2014 | 3:20 PM IST
Indian-origin scientists have developed a non-invasive method to fight heart disease by creating sticky nanoparticles that can deliver drugs targeting damaged arteries.
One of the standard ways to treat clogged and damaged arteries currently is to implant vascular stents, which hold the vessels open and release such drugs as paclitaxel.
The researchers, led by Clemson University's bioengineering professor Naren Vyavahare, hope their advanced nanoparticles could be used alongside stents or in place of them.
"Healthy arteries have elastic fibres that provide elasticity. They are like rubber bands in the tissue that allow expansion and recoil during blood flow," Vyavahare said.
"In most cardiovascular diseases, elastic fibres in arteries get damaged, creating hooks that can be used to target drugs," Vyavahare said.
The nanoparticles, coated with a sticky protein, latch onto damaged arteries and can deliver a drug to the site in slow release fashion.
These nanoparticles can be engineered to deliver an array of drugs to the damaged or clogged artery, a common example being paclitaxel, which inhibits cell division and helps prevent growth of scar tissue that can clog arteries.
These particles also have unique surfaces that allow prolonged circulation time, providing more opportunities for these particles to accumulate at the damage site.
"We developed nanoparticles that have antibodies on the surface that attach to diseased sites like Velcro," said Vyavahare.
"Interestingly, these newly created nanoparticles only accumulate at the damaged artery, not in the healthy arteries, enabling site-specific drug delivery," Vyavahare said.
"These nanoparticles can be delivered intravenously to target injured areas and can administer drugs over longer periods of time, thus avoiding repeated surgical interventions at the disease site," said Aditi Sinha, a Clemson graduate student and lead author of the study.
The study will be published in the journal Nanomedicine: Nanotechnolgy, Biology and Medicine.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 19 2014 | 3:20 PM IST

Next Story